Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sdBCMA.BBz CAR-T cells
- Development stage
- Preclinical
- Lead developer
- BC Cancer Research Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
sdBCMA.BBz CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of multiple myeloma. The therapy utilizes a single-domain antibody (sdAb or nanobody) targeting B-cell maturation antigen (BCMA; TNFRSF17) linked to a 4-1BB (BB) co-stimulatory domain and a CD3zeta (z) signaling domain. Developed through a collaboration involving the National Research Council Canada, BC Cancer Research Institute, the University of Calgary, and the University of California, San Francisco, these CAR-T cells are designed to provide effective anti-tumor activity against BCMA-expressing multiple myeloma cells. To address the risk of cytokine release syndrome (CRS) and inhibit IL-6-driven myeloma growth, researchers have also engineered versions of the sdBCMA.BBz construct that incorporate membrane-bound or secreted single-domain antibodies that neutralize interleukin-6 (IL-6). The therapy is currently in preclinical development.
- Other names
- BCMA-sdAb-BBz CAR-T cellsCanadian-made single domain antibody BCMA CAR-T cellssdBCMA.BBz CAR-T
02
Targets
TNFRSF9 (CD137 extracellular domain)TNFSF13 (APRIL)BAFF (Tumor necrosis factor ligand superfamily member 13B)BCMA (B-cell maturation antigen)CD247 (T-cell surface glycoprotein CD3 epsilon chain)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on sdBCMA.BBz CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sdBCMA.BBz CAR-T cells.